ARRAY BIOPHARMA INC's ticker is ARRY and the CUSIP is 04269X105. A total of 172 filers reported holding ARRAY BIOPHARMA INC in Q3 2016. The put-call ratio across all filers is 1.45 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $1,018,000 | +1070.1% | 21,968 | +515.9% | 0.00% | – |
| Q1 2019 | $87,000 | +4.8% | 3,567 | -39.3% | 0.00% | – |
| Q4 2018 | $83,000 | +38.3% | 5,879 | +47.3% | 0.00% | – |
| Q3 2018 | $60,000 | -10.4% | 3,991 | -1.3% | 0.00% | – |
| Q2 2018 | $67,000 | +63.4% | 4,043 | +61.2% | 0.00% | – |
| Q1 2018 | $41,000 | +28.1% | 2,508 | 0.0% | 0.00% | – |
| Q4 2017 | $32,000 | +68.4% | 2,508 | +66.3% | 0.00% | – |
| Q3 2017 | $19,000 | -98.6% | 1,508 | -99.1% | 0.00% | -100.0% |
| Q2 2017 | $1,376,000 | +10484.6% | 164,408 | +10802.4% | 0.00% | – |
| Q1 2017 | $13,000 | +8.3% | 1,508 | 0.0% | 0.00% | – |
| Q4 2016 | $12,000 | +300.0% | 1,508 | +281.8% | 0.00% | – |
| Q3 2016 | $3,000 | +200.0% | 395 | 0.0% | 0.00% | – |
| Q2 2016 | $1,000 | -50.0% | 395 | -50.0% | 0.00% | – |
| Q1 2016 | $2,000 | -33.3% | 790 | 0.0% | 0.00% | – |
| Q4 2015 | $3,000 | -78.6% | 790 | -74.6% | 0.00% | – |
| Q2 2014 | $14,000 | – | 3,110 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Redmile Group, LLC | 16,618,776 | $146,079,000 | 12.59% |
| BVF INC/IL | 4,986,186 | $43,829,000 | 8.81% |
| First Light Asset Management, LLC | 1,000,361 | $8,793,000 | 3.86% |
| Crosspoint Capital Strategies, LLC | 463,005 | $4,070,000 | 3.62% |
| Consonance Capital Management LP | 2,723,471 | $23,912,000 | 2.63% |
| KOPP INVESTMENT ADVISORS LLC | 219,926 | $1,933,000 | 2.04% |
| SPHERA FUNDS MANAGEMENT LTD. | 900,000 | $7,911,000 | 2.00% |
| Orbimed Advisors | 16,088,800 | $141,421,000 | 1.80% |
| Cormorant Asset Management, LP | 1,150,000 | $10,109,000 | 1.36% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 2,073,680 | $18,227,000 | 1.26% |